Toxicity and therapeutic efficacy of amphotericin B delivered through cholesterol hemisuccinate vesicles in the treatment of experimental murine aspergillosis

Journal of Antimicrobial Chemotherapy

Volumn 42, Issue 5, 1998, Pages 635-642

  Saxena, Sandeep ^a   Khan, Junaid A ^a   Ghosh, Prahlad C ^a  

^a UNIVERSITY OF DELHI   (India)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; CHOLESTEROL HYDROGEN SUCCINATE; DEOXYCHOLIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIFUNGAL ACTIVITY; ARTICLE; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; COLONY FORMING UNIT; CONTROLLED STUDY; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; ERYTHROCYTE; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY; LIVER; LUNG; MALE; MOUSE; NEPHROTOXICITY; NONHUMAN; SPLEEN; SURVIVAL;

AMPHOTERICIN B; ANIMALS; ANTIBIOTICS, ANTIFUNGAL; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; CHOLESTEROL; COLONY COUNT, MICROBIAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DELIVERY SYSTEMS; MALE; MICE; MICE, INBRED BALB C;

EID: 0031739389     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/42.5.635     Document Type: Article

References (42)

1. Denning, D. W. & Stevens, D. A. (1990). Antifungal and surgical treatment of invasive aspergillosis: review of 2,121 published cases. Reviews of Infectious Diseases 12, 1147-201.
2. Fraser, D. W., Ward, J. I., Ajello, L. & Plikaytis, B. D. (1979). Aspergillosis and other systemic mycosis. The growing problem. Journal of the American Medical Association 242, 1631-5.
3. Medoff, G., Brajtburg, J., Kobayashi, G. S. & Bolard, J. (1983). Antifungal agents useful in therapy of systemic fungal infections. Annual Review of Pharmacology and Toxicology 23, 303-30.
4. De Kruijff, B., Gerritsen, W. J., Oerlemans, A., Demel, R. A. & van Deenen, L. L. M. (1974). Polyene antibiotic-sterol interactions in the membrane of Acholeplasma ladlawii cells and lecithin liposomes. I. Specificity of the membrane permeability changes induced by polyene antibiotics. Biochimica et Biophysica Acta 339, 30-43.
5. Maddux, M. S. & Barrière, S. L. (1980). A review of complications of amphotericin B therapy: recommendations for prevention and management. Drug Intelligence and Clinical Pharmacy 14, 177-81.
6. Gregoriadis, G. (1978). Liposomes in therapeutic and preventive medicine: the development of the drug-carrier concept. Annals of the New York Academy of Sciences 308, 343-70.
7. Hiemenz, J. W. & Walsh, T. J. (1996). Lipid formulations of amphotericin B: recent progress and future directions. Clinical Infectious Diseases 22, Suppl. 2, S133-44.
8. Lopez-Berestein, G., Fainstein, V., Hopfer, R. L., Mehta, K., Sullivan, M. P., Keating, M. et al. (1985). Liposomal amphotericin B for the treatment of systemic fungal infections in patients with cancer: a preliminary study. Journal of Infectious Diseases 151, 704-10.
9. Adler-Moore, J. P., Chiang, S. M., Satorius, A., Guerra, D., McAndrews, B., McManus, E. J. et al. (1991). Treatment of murine candidosis and cryptococcosis with a unilamellar liposomal amphotericin B formulation (AmBisome). Journal of Antimicrobial Chemotherapy 28, Suppl. B, 63-71.
10. Clark, J. M., Whitney, R. R., Olsen, S. J., George, R. J., Swerdel, M. R., Kunselman, L. et al. (1991). Amphotericin B lipid complex therapy of experimental fungal infections in mice. Antimicrobial Agents and Chemotherapy 35, 615-21.
11. Kan, V. L., Bennett, J. E., Amantea, M. A., Smolskis, M. C., McManus, E., Grasela, D. M. et al. (1991). Comparative safety, tolerance, and pharmacokinetics of amphotericin B lipid complex and amphotericin B deoxycholate in healthy male volunteers. Journal of Infectious Diseases 164, 418-21.
12. Fielding, R. M., Smith, P. C., Wang, L. H., Porter, J. & Guo, L. S. S. (1991). Comparative pharmacokinetics of amphotericin B after administration of a novel colloidal delivery system, ABCD, and a conventional formulation to rat. Antimicrobial Agents and Chemotherapy 35, 1208-13.
13. Fielding, R. M., Singer, A. W., Wang, L. H., Babbar, S. & Guo, L. S. S. (1992). Relationship of pharmacokinetics and drug distribution in tissue to increased safety of amphotericin B colloidal dispersion in dogs. Antimicrobial Agents and Chemotherapy 36, 299-307.
14. Allende, M. C., Lee, J. W., Francis, P., Garrett, K., Dollenberg, H., Berenguer, J. et al. (1994). Dose-dependent antifungal activity and nephrotoxicity of amphotericin B colloidal dispersion in experimental pulmonary aspergillosis. Antimicrobial Agents and Chemotherapy 38, 518-22.
15. Patterson, T. F., Miniter, P., Dijkstra, J., Szoka, F. C., Ryan, J. L. & Andriole, V. T. (1989). Treatment of experimental invasive aspergillosis with novel amphotericin B/cholesterol-sulfate complexes. Journal of Infectious Diseases 159, 717-24.
16. Brockerhoff, H. & Ramsammy, L. S. (1982). Preparation and structural studies of cholesterol bilayers. Biochimica et Biophysica Acta 691, 227-32.
17. Janoff, A. S., Popenscu, C. M., Weener, A. L., Bolcsak, L. E., Tremblay, P. A. & Swenson, C. E. (1993). Compositions containing tris salt of cholesterol hemisuccinate and antifungal. US Patent no. 5,231, 112.
18. Ahmad, I., Sarkar, A. K. & Bachhawat, B. K. (1989). Liposomal amphotericin-B in the control of experimental aspergillosis in mice: Part I: Relative therapeutic efficacy of free and liposomal amphotericin-B. Indian Journal of Biochemistry and Biophysics 26, 351-6.
19. Nag, A., Mitra, G. & Ghosh, P. C. (1997). A colorimetric estimation of polyethyleneglycol-conjugated phospholipid in stealth liposomes. Analytical Biochemistry 250, 35-43.
20. 125I-labeled inulin: a convenient marker for deposition of liposomal contents in vivo. Biochemical and Biophysical Research Communications 122, 319-24.
21. Munshi, N., Chakarvorty, K., De, T. K. & Maitra, A. N. (1995). Activity and stability studies of ultrafine nanoencapsulated catalase and penicillinase. Colloid Polymer Science 273, 464-72.
22. Mehta, R. T., Hopfer, R. L., Juliano, R. L. & Lopez-Berestein, G. (1989). A comparison of in vitro toxicity and antifungal efficacy of membrane-active drugs after liposome encapsulation. Selective Cancer Therapeutics 5, 113-7.
23. Forster, D., Washington, C. & Davis, S. S. (1988). Toxicity of solubilized and colloidal amphotericin B formulations to human erythrocytes. Journal of Pharmacy and Pharmacology 40, 325-8.
24. Moonis, M., Ahmad, I. & Bachhawat, B. K. (1993). Mannosylated liposomes as carriers for hamycin in the treatment of experimental aspergillosis in Balb/c mice. Journal of Drug Targeting 1, 147-55.
25. Walsh, T. J. & Pizzo, P. A. (1994). In Infectious Diseases, 5th edn (Hoeprich, P. D., Jordan, C. & Ronald, A. R., Eds), pp. 541-7. J. B. Lippincott, Philadelphia, PA.
26. Meyer, R. D., Young, L. S., Armstrong, D. & Yu, B. (1973). Aspergillosis complicating neoplastic disease. American Journal of Medicine 54, 6-15.
27. Moonis, M., Ahmad, I. & Bachhawat, B. K. (1992). Liposomal hamycin in the control of experimental aspergillosis in mice: relative toxicity, therapeutic efficacy and tissue distribution of free and liposomal hamycin. Indian Journal of Biochemistry and Biophysics 29, 339-45.
28. de Marie, S., Janknegt, R. & Bakker-Woudenberg, I. A. J. M. (1994). Clinical use of liposomal and lipid-complexed amphotericin B. Journal of Antimicrobial Chemotherapy 33, 907-16.
29. Janknegt, R., de Marie, S., Bakker-Woudenberg, I. A. J. M. & Crommelin, D. J. A. (1992). Liposomal and lipid formulations of amphotericin B. Clinical pharmacokinetics. Clinical Pharmacokinetics 23, 279-91.
30. Abra, R. (1989). Amphotericin B/cholesteryl sulfate composition. US Patent no. 4,822,777.
31. Ringden, O., Meunier, F., Tollemar, J., Ricci, P., Tura, S., Kuse, E. et al. (1991). Efficacy of amphotericin B encapsulated in liposomes (AmBisome) in the treatment of invasive fungal infections in immunocompromised patients. Journal of Antimicrobial Chemotherapy 28, Suppl. B, 73-82.
32. Coker, R. J., Viviani, M., Gazzard, B. G., Du Pont, B., Pohle, H. D., Murphy, S. M. et al. (1993). Treatment of cryptococcosis with liposomal amphotericin B (AmBisome) in 23 patients with AIDS. AIDS 7, 829-35.
33. Graybill, J. R., Sharkey, P. K., Vincent, D., Johnson, E. Fan Havard, P. & Eng, R. (1991). Amphotericin B lipid complex (ABLC) in treatment (Rx) of cryptococcal meningitis (CM) in patients with AIDS. In Program and Abstracts of the Thirty-First Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 1991. Abstract 289, American Society for Microbiology, Washington, DC.
34. Lasic, D. D. (1988). The mechanism of vesicle formation. Biochemical Journal 256, 1-11.
35. Clemons, K. V. & Stevens, D. A. (1991). Comparative efficacy of amphotericin B colloidal dispersion and amphotericin B deoxycholate suspension in treatment of murine coccidioidomycosis. Antimicrobial Agents and Chemotherapy 35, 1829-33.
36. Hostetler, J. S., Clemons, K. V., Hanson, L. H. & Stevens, D. A. (1992). Efficacy and safety of amphotericin B colloidal dispersion compared with those of amphotericin B deoxycholate suspension for treatment of disseminated murine cryptococcosis. Antimicrobial Agents and Chemotherapy 36, 2656-60.
37. Proffitt, R. T., Satorius, A., Chiang, S. M., Sullivan, L. & Adler-Moore, J. P. (1991). Pharmocology and toxicology of a liposomal formulation of amphotericin B (AmBisome) in rodents. Journal of Antimicrobial Chemotherapy 28, Suppl. B, 49-61.
38. Mitsutake, K., Kohno, S., Miyazaki, Y., Noda, T., Miyazaki, H., Miyazaki, T. et al. (1994). In vitro and in vivo antifungal activities of liposomal amphotericin B, and amphotericin B lipid complex. Mycopathologia 128, 13-7.
39. Gondal, J. A., Swartz, R. P. & Rahman, A. (1989). Therapeutic evaluation of free and liposome-encapsulated amphotericin B in the treatment of systemic candidiasis in mice. Antimicrobial Agents and Chemotherapy 33, 1544-8.
40. Allendoerfer, R., Yates, R. R., Sun, S. H. & Graybill, J. R. (1992). Comparison of amphotericin B lipid complex with amphotericin B and SCH 39304 in the treatment of murine coccidioidal meningitis. Journal of Medical and Veterinary Mycology 30, 377-84.
41. Wang, L. H., Fielding, R. M., Smith, P. C. & Guo, L. S. S. (1995). Comparative tissue distribution and elimination of amphotericin B colloidal dispersion (Amphocil) and Fungizone after repeated dosing in rats. Pharmaceutical Research 12, 275-83.
42. Moonis, M., Ahmad, I. & Bachhawat, B. K. (1993). Liposomal hamycin in the control of experimental aspergillosis in mice: effect of phosphatidic acid with and without cholesterol. Journal of Antimicrobial Chemotherapy 31, 569-79.